Works matching IS 15747891 AND DT 2019 AND VI 13 AND IP 7


Results: 11
    1
    2
    3
    4
    5
    6
    7
    8

    Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.

    Published in:
    Molecular Oncology, 2019, v. 13, n. 7, p. 1503, doi. 10.1002/1878-0261.12497
    By:
    • Oo, Zay Yar;
    • Proctor, Martina;
    • Stevenson, Alexander J.;
    • Nazareth, Deborah;
    • Fernando, Madushan;
    • Daignault, Sheena M.;
    • Lanagan, Catherine;
    • Walpole, Sebastian;
    • Bonazzi, Vanessa;
    • Škalamera, Dubravka;
    • Snell, Cameron;
    • Haass, Nikolas K.;
    • Larsen, Jill E.;
    • Gabrielli, Brian
    Publication type:
    Article
    9
    10
    11

    Issue Information.

    Published in:
    Molecular Oncology, 2019, v. 13, n. 7, p. 1465, doi. 10.1002/1878-0261.12339
    Publication type:
    Article